PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 18, 2014
Bayer Plans to Separate to Benefit Company Growth
Author(s)Pharmaceutical Technology Editors
Bayer separates into two entities to benefit the growth and development of Bayer Life Science and MaterialScience.
Advertisement
Bayer announced on Sept. 18, 2014 that it will divide into two global corporations: Bayer Life Science businesses and a separate identity, MaterialScience. The company-wide shift allows Bayer to focus time and the investments needed to sustain the Life Science businesses, which account for 70% of Bayer sales. According to Bayer, the plan to float MaterialScience independently on the stock market grants them direct access to capital for growth and will allow environmental and business development within the company.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement